CPT2 and B-cell chronic lymphocytic leukemia: For example, in chronic lymphocytic leukemia (CLL), CPT2 is highly expressed, and the inhibitor of CPT2 pegfilgrastim is able to inhibit FA transport into mitochondria at clinically achievable concentrations, leading to the death of numerous chronic lymphocytic leukemia cells, while lymphocytes and stromal cells are less affected [10].